Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer

Understanding the Landscape of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) represents one of the most challenging subtypes of breast malignancy. Defined by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2), it does not respond to hormonal therapies or HER2-targeted drugs. TNBC is known for its aggressive clinical behavior, high grade of malignancy, and a tendency to recur within the first few years following diagnosis. For patients with high-risk features, such as regional lymph node involvement or high cellular proliferation markers like Ki-67, the risk of early relapse is particularly concerning. Historically, the standard of care has relied heavily on anthracycline and taxane-based chemotherapy, but researchers have long sought ways to intensify treatment to improve long-term survival outcomes.

The CITRINE Trial: A Specialized Approach to Intensified Therapy

The CITRINE trial (NCT04296175) was designed as a randomized, open-label, phase 3 trial to determine whether adding carboplatin—a platinum-based chemotherapy agent—to the standard adjuvant regimen could improve outcomes for this specific high-risk population. Conducted at the Fudan University Shanghai Cancer Center between March 2020 and March 2022, the study focused on women with operable high-risk TNBC. High risk was specifically defined as having positive regional nodes or being node-negative but possessing a Ki-67 labeling index of 50 percent or higher. This differentiation is crucial because it targets the patients most likely to benefit from more aggressive systemic treatment.

Experimental Design and Dosing Regimens

The study enrolled 808 patients, who were randomized into two groups. The carboplatin arm received a dose-dense or intensified regimen: four cycles of epirubicin and cyclophosphamide every two weeks, followed by four cycles of weekly paclitaxel combined with carboplatin. The control arm received the standard sequence: four cycles of epirubicin and cyclophosphamide (every two or three weeks), followed by four cycles of weekly paclitaxel without the addition of carboplatin. By incorporating carboplatin into the taxane phase of treatment, the researchers aimed to exploit the DNA-damaging capabilities of platinum agents, which have shown particular efficacy in cancers with DNA repair deficiencies, a common trait in many TNBC cases.

Significant Improvements in Survival Outcomes

The results of the CITRINE trial, published in late 2024, indicate a clear benefit for the intensified regimen. At a median follow-up of 44.7 months, the estimated three-year disease-free survival (DFS) rate was 92.3 percent in the carboplatin group compared to 85.8 percent in the control group. This represents a significant 36 percent reduction in the risk of disease recurrence, second primary cancer, or death (hazard ratio 0.64). Beyond the primary endpoint, the secondary outcomes were equally encouraging. The carboplatin arm showed superior results in three-year recurrence-free survival (93.8 percent vs 88.3 percent), three-year distant disease-free survival (94.8 percent vs 89.8 percent), and, perhaps most importantly, overall survival (98.0 percent vs 94.0 percent). These findings suggest that the addition of carboplatin does not just delay recurrence but may actually increase the cure rate for high-risk patients.

Analyzing the Timing of Therapeutic Benefit

One of the most intriguing findings from the CITRINE study was the temporal nature of the treatment effect. Statistical analysis revealed that the benefit of carboplatin was not uniform over time. A piecewise hazard model showed that the hazard ratio was most dramatic—0.31—during the first 12 months. This indicates that carboplatin is exceptionally effective at preventing the early relapses that often plague TNBC patients. As the time from surgery increased, the hazard ratio shifted closer to 1.0, suggesting that the most critical window for carboplatin’s impact is the immediate post-operative period. This insight allows clinicians to better understand the biological behavior of the disease and how platinum agents intervene during the peak period of metastatic risk.

Safety Profile and Management of Side Effects

While the intensification of chemotherapy often raises concerns about toxicity, the CITRINE trial reported that the adverse effects were manageable. The incidence of grade 3-4 treatment-related adverse events was higher in the carboplatin arm (66.7 percent) than in the control arm (55.0 percent). The most common toxicities were hematological, including neutropenia and thrombocytopenia, which are expected with platinum-based therapy. Importantly, there were no treatment-related deaths, and the safety profile did not reveal any new or unexpected concerns. The researchers noted that while the treatment is more intensive, the clinical benefits in terms of survival outweigh the increased risk of transient side effects for this high-risk population.

Mechanism of Action: Why Platinum Works in TNBC

The success of carboplatin in this trial can be linked to the underlying biology of triple-negative breast cancer. Many TNBC tumors exhibit ‘BRCAness,’ a term describing a phenotype where the tumor has defects in homologous recombination DNA repair, similar to tumors with actual BRCA1 or BRCA2 mutations. Platinum agents like carboplatin work by creating interstrand cross-links in DNA. In cells with compromised repair mechanisms, these cross-links lead to double-strand breaks and subsequent cell death (apoptosis). By adding carboplatin to a taxane-based backbone, the treatment provides a multi-pronged attack on the cancer cell’s structural integrity and its ability to replicate.

The Clinical Implications for High-Risk TNBC Patients

The CITRINE trial provides robust evidence that the addition of carboplatin to an anthracycline and taxane-based adjuvant regimen should be considered a standard option for patients with high-risk, early-stage TNBC. The use of the Ki-67 index as a marker for high-risk status in node-negative patients is a particularly valuable takeaway, as it helps identify a subgroup that might otherwise be undertreated. For oncology professionals, these results reinforce the trend toward personalized intensification in breast cancer care, ensuring that the most aggressive treatments are reserved for the most aggressive disease profiles. As we look forward, the integration of these findings into international guidelines could potentially save many lives by curbing the early recurrence rates that have historically defined the TNBC experience.